Piper Sandler Maintains Neutral on OncoCyte, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg has maintained a Neutral rating on OncoCyte (NASDAQ:OCX) and reduced the price target from $3.5 to $3.
November 13, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on OncoCyte and lowered the price target from $3.5 to $3, indicating a potential downside or limited upside.
The reduction in price target by a prominent analyst could lead to a negative perception among investors, potentially causing a short-term decline in OCX's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100